SHARE

Porton Unveils Its Small Molecule Platform Headquarters In Shanghai Porton Unveils Its Small Molecule Platform Headquarters In Shanghai
14.05.2023

Porton Unveils Its Small Molecule Platform Headquarters In Shanghai

Porton Unveils Its Small Molecule Platform Headquarters In Shanghai

On May 8, 2023, Porton Pharma Solutions Ltd. (stock code: 300363) celebrated the grand opening of its Small Molecule Business Platform Headquarters, located in Minhang Economic and Technological Development Zone, Shanghai. This momentous event attracted nearly 200 representatives ranging from local government, customers, investors, and academia. Mr. Yujian Chen, Secretary of Shanghai Minhang District, Mr. Rui Li, Deputy Mayor of Shanghai Minhang District, Mr. Xiaoming Feng, Party Secretary/Executive Director of Shanghai Land Minhang (Group) Co., Ltd, and Mr. Nianfeng (Oliver) Ju, Chairman and CEO of Porton, attended this ceremony.

Porton Unveils Its Small Molecule Platform Headquarters In Shanghai

The newly established headquarters and R&D center is located in No. 188 Beidou Road, Minhang District, Shanghai, which covers an area of more than 26 acres with two independent buildings. With an expansive 22,000 square meters of coverage, the facility hosts cutting-edge laboratories and synthesis facilities for a range of molecules.

Porton is also taking advantage of a large breadth of innovative technologies and capabilities at this site, including Bio-technology, Metal Catalysis, Flow Chemistry, Photo- and Electro- Chemistry, Crystallization, Milling and more. In addition, Porton has set up a new Synthetic Macromolecular Services Department here, covering an area of more than 3,000 square meters and equipped with state-of-the-art international standard laboratories, which will provide peptide drugs, oligonucleotide drugs, conjugate drugs, and other services for global pharmaceutical companies and new drug research organizations.

Porton Unveils Its Small Molecule Platform Headquarters In Shanghai

The Chairman and CEO of Porton, Mr. Ju Nianfeng, emphasized in his speech the company's unwavering commitment to its core principles, highlighting a customer-first mindset, a commitment to top talent, continual technological investment, and management innovation as the backbone of Porton's success.

Porton Unveils Its Small Molecule Platform Headquarters In Shanghai

At the opening ceremony, Porton Green Chemistry Research and Development Center was officially unveiled, marking another significant milestone in the company’s development of green chemistry. Starting from R&D, Porton follows the principles of green drug development, optimizing process parameters and control methods, actively developing and applying environmentally-friendly technologies such as biocatalysis, metal catalysis, flow chem, photo-electro chem and etc. to improve product yield, reducing waste generation and emissions, and recovering solvents and heavy metals. In the future, Porton Green Chemistry Research and Development Center will continue to utilize green chemistry and achieve high-quality and sustainable development for the industry.

Porton Unveils Its Small Molecule Platform Headquarters In Shanghai

With the establishment of the Small Molecule Platform Headquarters, Porton now boasts seven R&D and production facilities in Shanghai, covering end-to-end and full-category CDMO services such as drug substance, drug preparation, synthetic macromolecules and biological macromolecules (under construction).

Porton Unveils Its Small Molecule Platform Headquarters In Shanghai
Porton Unveils Its Small Molecule Platform Headquarters In Shanghai
Porton Unveils Its Small Molecule Platform Headquarters In Shanghai

About Porton

Founded in 2005, Porton Pharma Solutions Ltd.is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for small molecule, large molecule and gene and cell therapies from pre-clinical to commercialization. With more than 5000 skilled employees working across more than 20 sites around the globe, Porton is committed to becoming the most open, innovative and reliable pharmaceutical service platform in the world and enabling the public’s early access to good medicines. As the end of 2022, we have established business contacts with nearly 800 customers worldwide and has over 2,200 successful project delivery experiences.

SHARE

Porton Unveils Its Small Molecule Platform Headquarters In Shanghai Porton Unveils Its Small Molecule Platform Headquarters In Shanghai
Porton Experts Invited To Participate In The University Of Perugia Master PRO-API Program, Aiding In The Training Of Green Process Chemistry Professionals Porton Will Be Participating In Biotech Outsourcing Strategies Events This June Proton At CPhI North America Again Porton 2023 ESG Report Upcoming Porton Shows In Europe And The USA:Shaping Our Future Together Porton Makes Debut At DCAT Week 2024 To Jointly Promote Industry Development Join Our Founder And CEO @ DCAT Week Porton Pharma Solutions Joined The SBTi To Drive Climate Action Farewell To 2023, And WE Are Sailing Forward To 2024 The Pharma Crystallization Summit (PCS) Is Held Annually To Bring Together Developers Of New Medicines With Crystallization Challenges And The Crystallization Experts (Solution Providers) In The Industry And Academia. Porton Gets Improved In The 2023 S&P Global ESG Score Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services Pharma Digital Intelligence Summit Will Be Held On 5th, September, 2023 [Important Notice] Porton Announcement Regarding The Change Of Email Domain Porton Unveils Its Small Molecule Platform Headquarters In Shanghai PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai Porton At DCAT Week 2023: A Highly Successful And Strategic Event Porton Released 2022 CSR Report Porton Delivers Strong 2022 Performance With 127% Sales Growth Porton Gets Above-Average S&P Global Environmental, Social, And Governance (ESG) Score
News

Insights Unveiled: Delve into Our Global News Hub!

22.05.2024

Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia

  • Opening ceremony of the state-of-the-art research and development laboratories for active pharmaceutical ingredients, small molecules, of Porton in Mengeš

  • A donation of EUR 20,000.00 to the municipality of Mengeš for the restoration of a flooded kindergarten

  • New jobs and further growth in the field of API's small molecules in Slovenia, Mengeš

Read the news

Cookie settings

Your current status

Show details